Зипраcидон для внутримышечного введения: опыт и возможности применения в психиатрии

В.Э. Медведев 1, Т.С. Сюняков 2
1 Российский университет дружбы народов, Москва
2 ООО «Пфайзер», Москва

Резюме. В обзоре представлены данные об эффективности современного атипичного антипсихотика зипрасидона для внутримышечного применения при купировании острого психомоторного возбуждения различного генеза (шизофрения, биполярное аффективное расстройство, шизоаффективное расстройство, расстройства импульсивных влечений, алкогольная и другие виды интоксикации), в том числе в случаях недостаточной эффективности других инъекционных антипсихотиков (типичных и атипичных). Незначительная выраженность нежелательных эффектов и сходная эффективность внутримышечного зипрасидона у пациентов различного возраста позволяют применять препарат для купирования возбуждения у детей, подростков и пожилых людей, в том числе соматически неблагополучных. Разработанные схемы перевода больных с лечения зипрасидоном с инъекционной на пероральную форму препарата позволяют обеспечить фармакологическую преемственность терапии без потери эффективности лечения.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  • 1. Mautone A., Scarone S., all investigators. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial // Pharmacopsychiatry. – 2011. – Vol. 44, No. 5. – P. 173–178.
  • 2. Bosanac P., Hollander Y., Castle D. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation // Australas Psychiatry. – 2013. – Vol. 21, No. 6. – P. 554–562.
  • 3. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya pomoshch' v psikhiatrii // Neotlozhnaya pomoshch' v meditsinskoi praktike / pod red. A.B. Vertkina, B.S. Briskina. – M.: Litera, 2007. – S. 57–93.
  • 4. Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – 1080 s.
  • 5. Tsukarzi E.E. Neotlozhnaya pomoshch' pri agressivnom povedenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 2. – S. 31–40.
  • 6. Mosolov S.N., Tsukarzi E.E., Alfimov P.V. Algoritmy biologicheskoi terapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 1. – S. 27–36.
  • 7. Currier G.W., Trenton A. Pharmacological treatment of psychotic agitation. // CNS Drugs. – 2002. – Vol. 16, No. 4. – P. 219–228.
  • 8. Preval H. et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study // Gen Hosp Psychiatry. –2005. – Vol. 27, No. 2. – P. 140–144.
  • 9. Brook S., Lucey J. V, Gunn K.P. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group // J Clin Psychiatry. – 2000. – Vol. 61, No. 12. – P. 933–941.
  • 10. Medvedev V.E. Lechenie shizofrenii sovremennymi atipichnymi antipsikhoticheskimi preparatami: uchebno-metodich. posobie. – M.: OAO «Konti-Print», 2014. – 72 s.
  • 11. Lesem M.D. et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients // J Clin Psychiatry. – 2001. – Vol. 62, No. 1. – P. 12–18.
  • 12. Nordstrom K., Allen M.H. Managing the acutely agitated and psychotic patient // CNS Spectr. – 2007. – Vol. 12, No. 10, Suppl. 17. – P. 5–11.
  • 13. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – 1080 s.
  • 14. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya terapiya v psikhiatrii // Meditsina kriticheskikh sostoyanii. – 2004. – № 6. – S. 36–41.
  • 15. Chandrasena R. et al. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania // Int J Clin Pract. – 2009. – Vol. 63, No. 8. – P. 1249–1258.
  • 16. Mestre T.A., Zurowski M., Fox S.H. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders // Expert Opin Investig Drugs. – 2013. – Vol. 22, No. 4. – P. 411–421.
  • 17. Morozov P.V. Zeldoks (ziprasidon) – novyi atipichnyi neiroleptik // Psikhiatriya i psikhofarmakoterapiya. – 2005. Vol. 7, No. 5. – P. 264–268.
  • 18. Keck P.E., McElroy S.L. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications // J Clin Psychiatry. – 2002. – Vol. 63, Suppl 4. – P. 3–11.
  • 19. Wilson M.P. et al. Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting // J Emerg Med. – 2013. – Vol. 45, No. 6. – P. 901–908.
  • 20. Nemeroff C.B. et al. From clinical research to clinical practice: a 4-year review of ziprasidone // CNS Spectr. – 2005. – Vol. 10, No. 11, Suppl 17. – P. 1–20.
  • 21. Bykov Yu.V., Bekker R.A., Syunyakov T.S. Ziprasidon: balans mezhdu effektami, effektivnost'yu i perenosimost'yu // Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. – 2016. – № 4. – C. 52–62.
  • 22. Lacroix L.P. et al. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex // Synapse. – 2004. – Vol. 51, No. 2. – P. 158–164.
  • 23. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis // Prog Brain Res. – 2008. – Vol. 172. – P. 199–212.
  • 24. Newman-Tancredi A., Kleven M.S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties // Psychopharmacology (Berl). – 2011. – Vol. 216, No. 4. – P. 451–473.
  • 25. Park S.W. et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats // J Psychiatr Res. – 2009. – Vol. 43, No. 3. – P. 274–281.
  • 26. Kaengkan P. et al. Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats // Mol Cells. – 2013. – Vol. 36, No. 6. – P. 534–541.
  • 27. Benninghoff J. et al. Ziprasidone – Not Haloperidol – Induces more de-novo Neurogenesis of Adult Neural Stem Cells Derived from Murine Hippocampus // Pharmacopsychiatry. – 2012. – Vol. 46, No. 1. – P. 10–15.
  • 28. Rais A.R. et al. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study // Psychiatry (Edgmont). – 2010. – Vol. 7, No. 1. – P. 17–24.
  • 29. Brook S. et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study // Psychopharmacology (Berl). – 2005. – Vol. 178, No. 4. – P. 514–523.
  • 30. Zimbroff D.L. et al. Best clinical practice with ziprasidone IM: update after 2 years of experience // CNS Spectr. – 2005. – Vol. 10, No. 9. – P. 1–15.
  • 31. Weiden P.J. et al. Best clinical practice with ziprasidone: update after one year of experience // J Psychiatr Pract. – 2002. – Vol. 8, No. 2. – P. 81–97.
  • 32. Daniel D.G. et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial // Psychopharmacology (Berl). – 2001. – Vol. 155, No. 2. – P. 128–134.
  • 33. Lesem M.D. et al. Intramuscular Ziprasidone, 2 mg Versus 10 mg, in the Short-Term Management of Agitated Psychotic Patients // J Clin Psychiatry. Physicians Postgraduate Press, Inc. – 2001. – Vol. 62, No. 1. – P. 12–18.
  • 34. Baldaçara L. et al. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone // Rev Bras Psiquiatr. – 2011. – Vol. 33, No. 1. – P. 30–39.
  • 35. Zhang H. et al. Intramuscular Ziprasidone Versus Haloperidol for Managing Agitation in Chinese Patients With Schizophrenia // J Clin Psychopharmacol. – 2013. – Vol. 33, No. 2. – P. 178–185.
  • 36. Brook S. et al. Intramuscular Ziprasidone Compared With Intramuscular Haloperidol in the Treatment of Acute Psychosis // J Clin Psychiatry. – 2000. – Vol. 61, No. 12. – P. 933–941.
  • 37. Martínez-Formoso S. et al. P03-364 Comparison of intramuscular ziprasidone and haloperidol for acute psychotic agitation in an emergency room // Eur Psychiatry. – 2010. – Vol. 25.
  • 38. Fulton J.A. et al. Intramuscular ziprasidone: an effective agent for sedation of the agitated ED patient // Am J Emerg Med. – 2006. – Vol. 24, No. 2. – P. 254–255.
  • 39. Syunyakov T.S. Molekulyarnaya genetika i farmakogenetika bipolyarnogo affektivnogo rasstroistva // Psikhiatriya. – 2014. – T. 63, № 3. – C. 73–87.
  • 40. Citrome L. et al. Efficacy of Ziprasidone Against Hostility in Schizophrenia: Post Hoc Analysis of Randomized, Open-Label Study Data // J Clin Psychiatry. – 2006. – Vol. 67, No. 4. –P. 638–642.
  • 41. Swift R.H. et al. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients // J Psychiatr Res. – Vol. 36, No. 2. – P. 87–95.
  • 42. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale // Psychol Rep. – 1962. – Vol. 10, No. 3. – P. 799–812.
  • 43. Battaglia J. et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study // Am J Emerg Med. – 1997. – Vol. 15, No. 4. – P. 335–340.
  • 44. Citrome L. Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation: A Quantitative Review of Efficacy and Safety // J Clin Psychiatry. – 1876. – Vol. 68. – P. 1876–1885.
  • 45. Barak Y. et al. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia // Am J Geriatr Psychiatry. – 2006. – Vol. 14, No. 7. – P. 629–633.
  • 46. Kohen I. et al. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service // Am J Geriatr Pharmacother. – 2005. –Vol. 3, No. 4. – P. 240–245.
  • 47. Jangro W.C. et al. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study // Child Adolesc Psychiatry Ment Health. – 2009. – Vol. 3, No. 1. – P. 9.
  • 48. Barzman D.H. et al. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed // J Child Adolesc Psychopharmacol. – 2007. – Vol. 17, No. 4. – P. 503–509.
  • 49. Staller J.A. Intramuscular ziprasidone in youth: a retrospective chart review. // J Child Adolesc Psychopharmacol. – 2004. – Vol. 14, No. 4. – P. 590–592.
  • 50. Khan S.S., Mican L.M. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents // J Child Adolesc Psychopharmacol. – 2006. – Vol. 16, No. 6. – P. 671–677.
  • 51. Hazaray E. et al. Intramuscular ziprasidone for acute agitation in adolescents. // J Child Adolesc Psychopharmacol. – 2004. – Vol. 14, No. 3. – P. 464–470.
  • 52. Daniel D.G. Tolerability of ziprasidone: an expanding perspective // J Clin Psychiatry. – 2003. – Vol. 64, Suppl 1. – P. 40–49.
  • 53. Leung J.G. et al. Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost // Am J Ther. – 2011. – Vol. 18, No. 4. – P. 300–304.
  • 54. Cañas F. et al. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial // Clin Drug Investig. – 2007. – Vol. 27, No. 9. – P. 633–645.
  • 55. Baptista T. et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics // Curr Drug Targets. – 2004. – Vol. 5, No. 3. – P. 279–299.
  • 56. Mosolov S.N., Ryvkin P.V., Serditov O.V., Ladyzhenskii M.Ya., Potapov A.V. Metabolicheskie pobochnye effekty sovremennoi antipsikhoticheskoi farmakoterapii // Sotsial'naya i klinicheskaya psikhiatriya. – 2008. – T. 18, № 3. – S. 75–90.
  • 57. Alfimov P.V., Ryvkin P.V., Ladyzhenskii M.Ya., Mosolov S.N. Metabolicheskii sindrom u bol'nykh shizofreniei // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 3. – S. 8–14.
  • 58. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function // CNS Drugs. – 2002. – Vol. 16, No. 1. – P. 23–45.
  • 59. Miodownik C. et al. Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients // Clin Neuropharmacol. – Vol. 28, No. 6. – P. 295–297.